Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017, American College of Physicians

Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). Results of a comprehensive cost-effectiveness analysis suggest that patients who have RA and no contraindications to triple therapy should use it prior to a biologic as the next regimen. The study is published in Annals of Internal Medicine.

RA treatment begins with conventional disease-modifying anti-rheumatic drugs, such as methotrexate which are relatively inexpensive. Current guidelines from the American College of Rheumatology advocate adding a biologic, such as etanercept, if symptoms persist. Biologics are very expensive, but compared to continuing methotrexate, many experts have considered the health benefits are worth the cost.

Results of the recent Rheumatoid Arthritis Comparison of Active Therapies (RACAT) trial raise questions about the cost-effectiveness of this biologics-first approach. The trial found that triple , a combination of the inexpensive drugs sulfasalazine, hydroxychloroquine, and methotrexate is as effective as switching directly to biologics. Despite this evidence, few patients with RA are transitioned to triple therapy.

Researchers in US and Canada funded by the Cooperative Studies Program of the Department of Veterans Affairs and the Canadian Institutes for Health Research compared the and benefits of etanercept-methotrexate first versus triple therapy first in 353 patients enrolled in the RACAT trial who continued to have uncontrolled symptoms of RA after at least 12 weeks of therapy. The researchers measured incremental costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness rations (ICERs) at 24 months and a lifetime. They forecast a scenario where etanercept would improve outcomes due to preventing joint erosions beyond the trial horizon.

The analysis showed that treating with the biologic therapy first provided marginally more benefits, but an amount that would not be detectable to patients. The lifetime analysis suggested that first-line biologic treatment would result in 0.15 additional lifetime QALYs, but this gain would cost an incremental $77,290, leading to an incremental cost-effectiveness ratio of $521,520 per QALY per patient, a figure far above what is considered acceptable to the U.S. health care system. As such, the authors conclude that patients, unless contraindicated, should switch to first before switching to a biologic strategy. The authors cite literature showing this is a strategy that many would prefer anyway, since it could reduce their out-of-pocket costs, and would not expose them to the risk of serious side-effects associated with biologic therapy.

Explore further: Cheaper drugs produce same benefits for rheumatoid arthritis, study finds

More information: Switching directly to biologic therapy when methotrexate fails is not cost effective for treating rheumatoid arthritis, Annals of Internal Medicine (2017). annals.org/aim/article/doi/10.7326/M16-0713

Editorial: Annals of Internal Medicine (2017). annals.org/aim/article/doi/10.7326/M17-1176

Related Stories

Cheaper drugs produce same benefits for rheumatoid arthritis, study finds

June 13, 2013
James O'Dell, M.D., chief of the Veterans Administration Nebraska-Western Iowa Health Care System's Omaha medical center and the UNMC divisions of rheumatology and immunology, is the primary author of a study that has been ...

Apixaban Tx cost in A-fib meets U.S. norms for reasonable value

March 31, 2017
(HealthDay)—Apixaban therapy is cost-effective for atrial fibrillation from the perspective of the U.S. health care system, according to a study published online March 29 in JAMA Cardiology.

Evidence-based recs issued for systemic care in psoriasis

December 19, 2014
(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy with minimized ...

Intensive initial therapy with triple DMARDs improves functional ability in early RA

June 10, 2015
The results of the tREACH trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that initial therapy with combination DMARDs significantly improves measures of ...

Data suggest smoking doesn't impact RA treatment response

December 21, 2012
(HealthDay)—For patients with early rheumatoid arthritis (RA), smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according to a study ...

Staying on dmards through surgery does not increase post-op infection risk

November 13, 2016
Rheumatoid arthritis patients who keep using their disease-modifying antirheumatic drugs prior to surgery do not face an increased risk of infection after their procedures, according to new research findings presented this ...

Recommended for you

How environmental pollutants and genetics work together in rheumatoid arthritis

April 19, 2018
It has been known for more than three decades that individuals with a particular version of a gene—human leukocyte antigen (HLA)—have an increased risk for rheumatoid arthritis.

The bugs in your gut could make you weak in the knees

April 19, 2018
Bacteria in the gut, known as the gut microbiome, could be the culprit behind arthritis and joint pain that plagues people who are obese, according to a new study published today in JCI Insight.

Researchers identify peptide produced during cartilage deterioration as a potential source of osteoarthritis pain

April 11, 2018
Osteoarthritis is one of the most common causes of chronic pain in the world. More than 30 million people in the United States alone suffer from osteoarthritis, or OA, which can affect any moveable joint of the body, including ...

Flare-responsive hydrogel developed to treat arthritis

April 3, 2018
Arthritis flares - the unpredictable and often sudden worsening of arthritis symptoms—can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic ...

Drug compound shows promise against rheumatoid arthritis

March 28, 2018
Scientists have designed a new drug compound that dials down inflammation, suggesting possible future uses against autoimmune disorders such as rheumatoid arthritis.

Chromosomal loop signatures could identify poor drug response in arthritis

March 28, 2018
Chromosomal loop signatures found in blood samples obtained in early rheumatoid arthritis could identify patients that will not respond adequately to 'anchor' treatment drug methotrexate.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.